10-K: ResMed Reports Strong FY25 Growth, Boosted by Digital Health

ResMed Inc. announced a robust fiscal year 2025, with significant revenue and profit increases driven by its digital health and sleep & breathing solutions.

Summary

• Net revenue for fiscal year 2025 increased by 10% to $5,146.3 million, up from $4,685.3 million in fiscal year 2024.
• Gross profit rose by 15% to $3,055.0 million, with the gross margin improving to 59.4% from 56.7% in the prior year.
• Net income for fiscal year 2025 was $1,400.7 million, a 37.2% increase from $1,021.0 million in fiscal year 2024.
• Diluted earnings per share (EPS) increased by 37.4% to $9.51 in fiscal year 2025, compared to $6.92 in fiscal year 2024.
• Cash and cash equivalents significantly increased to $1,209.5 million as of June 30, 2025, from $238.4 million in the prior year.
• Long-term debt, net, decreased to $658.4 million from $697.3 million.
• The effective income tax rate decreased to 16.5% from 19.3% in the prior year, primarily due to IRS refunds and tax benefits from business cessation.
• Acquired VirtuOx in May 2025, a software-enabled independent diagnostic testing facility, to expand home-based diagnostics and patient monitoring capabilities.
• Launched the NightOwl home sleep apnea test across the U.S. in April 2025, simplifying OSA diagnosis.

Sentiment

Score: 8

Explanation: The company delivered strong financial results across key metrics, including significant revenue, profit, and EPS growth, coupled with improved margins and a strengthened balance sheet. Strategic acquisitions and continued investment in R&D for digital health solutions position it well for future growth, despite acknowledging competitive and regulatory challenges.

Positives

• Achieved strong financial growth with a 10% increase in net revenue and a 37.2% increase in net income year-over-year.
• Improved gross margin to 59.4% due to procurement, manufacturing, and logistics efficiencies, and reduced field safety notification expenses.
• Significantly increased cash and cash equivalents to over $1.2 billion, demonstrating strong liquidity.
• Reduced long-term debt, strengthening the balance sheet.
• Successfully acquired VirtuOx, enhancing the company's end-to-end solutions in sleep and breathing health diagnostics.
• Continued investment in research and development, totaling $331.3 million, focusing on AI/ML integration and digital health innovations.
• The effective tax rate decreased to 16.5% due to favorable IRS refunds and tax benefits from business cessation.
• Positive developments in patent litigation, with PTAB invalidating NYU's asserted patents and instituting Inter Partes Review proceedings against Cleveland Medical's patents.

Negatives

• Incurred losses on equity investments totaling $10.3 million in fiscal year 2025.
• Increased selling, general, and administrative expenses by 8% and research and development expenses by 8% year-over-year.
• Faces potential negative impacts from the reintroduction of products by major competitor Philips.
• Anticipates a 2.93% reduction in average Medicare payment rates under the Physician Fee Schedule in CY 2025, though temporarily addressed for 2026.
• Proposed changes to VA disability ratings for sleep apnea could reduce the number of veterans seeking CPAP treatment or lead to claims of ineffective treatment.
• The 'One Big Beautiful Bill Act' is projected to cut federal Medicaid funding by $930 billion over ten years and increase the number of uninsured individuals by 11.8 million by 2034, potentially reducing demand for products and services.
• Medicare telehealth flexibilities are set to expire at the end of 2025, which could adversely impact OSA diagnosis rates.

Risks

• Inability to compete with new and existing technologies, including pharmaceuticals like GLP-1 weight loss drugs that may reduce OSA severity.
• Consolidation in the healthcare industry could lead to increased competition and pressure on product pricing.
• Global macroeconomic conditions, including inflation, supply chain disruptions (e.g., Red Sea shipping, semiconductor chips, magnets), and foreign currency exchange rate fluctuations, could adversely affect operations and profitability.
• Public health crises, pandemics, or epidemics could harm business, financial condition, and results of operations.
• International activities are subject to various risks, including currency fluctuations, trade barriers, regulatory compliance, and geopolitical tensions.
• Unfavorable or inconsistent results from clinical trials could impact product clearances, approvals, and market share.
• Potential product liability claims that may exceed insurance coverage.
• Intellectual property may not adequately protect products, or products may infringe on third-party rights, leading to costly litigation.
• Failure to source, develop, and retain key employees could negatively impact the business.
• Leverage and debt service obligations could adversely affect the business.
• The acquisition of VirtuOx introduces new areas of direct healthcare oversight by federal government agencies, increasing compliance efforts and potential liabilities.
• Disruptions in the supply of components from single-source suppliers or due to export controls could reduce sales and profitability.
• Increasing dependence on information technology systems and infrastructure, making the company vulnerable to cyberattacks and data breaches.
• Inability to realize anticipated benefits from acquisitions, leading to unforeseen operating difficulties and expenditures.
• Failure to effectively manage continued growth or achieve expected operating efficiencies could lead to increased costs and reduced business results.
• Dependence on effective marketing to home healthcare product dealers, sleep clinics, and physicians.
• The success of software offerings relies on customer renewals, upgrades, and expansions, which may decline.
• Software product failures or lack of enhancements could lead to customer loss and warranty claims.
• Interruptions or performance problems with technology or infrastructure for software services.
• Climate change and natural disasters could negatively impact business operations and financial condition.
• Healthcare reform or other cost-cutting measures by government or commercial payors may materially affect the industry and results of operations.
• Government and private insurance plans may not adequately reimburse customers for products, leading to reduced sales or selling prices.
• Non-compliance with fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act) and transparency laws (e.g., Physician Payments Sunshine Act, HIPAA, CCPA, GDPR, AI laws) could result in significant penalties and reputational harm.
• Product sales, introductions, or modifications may be delayed or canceled due to FDA or similar foreign regulations.
• Failure to comply with quality standards (e.g., QSR, QMSR, ISO 13485, MDR) could lead to enforcement actions.
• Disruptions at the FDA and other government agencies could hinder product development and commercialization.
• Off-label marketing of products could result in substantial penalties.
• Laws regulating consumer contacts could adversely affect business operations or create liabilities.
• Evolving tax laws, regulations, and enforcement practices (e.g., Pillar Two global minimum tax, IRC Section 174 changes) may cause increased expense and management distraction.
• Ongoing tax audits by local tax authorities could result in material adjustments to financial results.
• Sustainability and corporate governance issues are evolving, leading to additional investment and expense.
• Quarterly operating results are subject to fluctuation for a variety of reasons.
• Dividend declarations and share repurchase programs are subject to board discretion.
• Delaware law and charter provisions could make it difficult for another company to acquire ResMed.

Future Outlook

The company anticipates continued growth in sleep and breathing treatments, driven by increasing awareness of conditions like OSA and COPD, improved understanding of therapy roles, and expanded use of digital health technology. It aims to further differentiate products through AI and machine learning integration and simplify care pathways. The company expects a new CMS national coverage determination for respiratory assist devices in September 2025 and will monitor potential changes to VA disability ratings for sleep apnea. It also expects increased costs to monitor and respond to evolving healthcare reform measures from the Trump Administration and Congress, and anticipates the Pillar Two global minimum tax to impact its effective tax rate in fiscal year 2026. Operations are expected to transition from Chatsworth, California to Calabasas, California during fiscal year 2026.

Management Comments

• We are a global leader in digital health and cloud-connected medical devices. We design innovative solutions to treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives.
• Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases.
• The acquisition of VirtuOx strengthens our position in the sleep and breathing health market by expanding our ability to offer end-to-end solutions, including home-based diagnostics and patient monitoring.
• We envision a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home.
• Digital enablement is central to our strategy.
• We are committed to ongoing investment in research and development and product enhancements.
• Our culture is designed to unlock the potential, skills, engagement and creativity of our people.
• We believe that our current sources of liquidity will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond.

Industry Context

The sleep and breathing health market remains globally underpenetrated, offering significant growth opportunities for ResMed's innovative products. The residential care market is fragmented and underserved, providing a fertile ground for the company's software solutions. The industry is seeing an enhanced focus on sleep apnea due to new pharmaceutical treatments and consumer technology, which could both create opportunities and introduce new competitive pressures. The regulatory landscape is rapidly evolving with new FDA regulations (QMSR), EU AI Act, and ongoing changes in U.S. healthcare policy (Medicare, Medicaid, VA), requiring continuous adaptation. The temporary absence of a major competitor, Philips, has created market opportunities, but its eventual return is expected to intensify competition.

Comparison to Industry Standards

• The company maintains its position as a global leader in digital health and cloud-connected medical devices, indicating strong performance relative to the broader industry.
• ResMed is recognized as a leader in developing smaller, quieter, more comfortable, and more connected products for sleep apnea, suggesting superior product innovation compared to competitors.
• The company's quality management system is certified to ISO 13485 and MDSAP, and is adapting to the new FDA QMSR, demonstrating adherence to high global quality and regulatory benchmarks.
• The company's Residential Care Software solutions are described as 'leading,' implying strong market position and effectiveness within that segment.

Corporate Governance

Legal Proceedings

• NYU Patent Infringement: NYU filed a complaint on June 2, 2021, alleging infringement of several patents by ResMed's AutoSet or AutoRamp features. The PTAB invalidated NYU's patents in December 2023, which NYU appealed to the Federal Circuit on January 31, 2024. Oral argument is scheduled for August 2025.
• Cleveland Medical Devices Inc. Patent Infringement: Cleveland Medical filed suit on June 16, 2022, alleging infringement by ResMed's connected devices and data platforms. ResMed Corp. filed petitions with the PTAB for Inter Partes Review of Cleveland Medical's patents, with some instituted in May/June/July 2025 and final decisions expected by July 2026. The District Court of the Northern District of Ohio granted ResMed Corp.'s motion to stay the case pending PTAB conclusions.
• U.S. Department of Justice Settlement (2019): ResMed settled five False Claims Act lawsuits for $39.5 million in December 2019, related to providing free services/products. A five-year Corporate Integrity Agreement (CIA) was entered, with most obligations expiring on December 18, 2024.
• VirtuOx Settlement (2022): VirtuOx (acquired by ResMed in May 2025) entered a civil settlement of $3.2 million and a five-year CIA with the OIG on May 11, 2022, for False Claims Act violations related to billing practices. VirtuOx will be under the CIA through 2027.

Stakeholder Impact

• Shareholders: Positive financial performance, increased dividends, and share repurchases are beneficial. Corporate governance changes may affect shareholder rights and engagement.
• Employees: Continued focus on inclusive environment, mentorship, learning, competitive compensation, and health/safety programs. Restructuring activities in FY24 involved severance, impacting some employees.
• Customers (HME providers, sleep clinics, hospitals, residential care providers): Benefit from new product launches and software solutions for efficiency and patient care. Face ongoing price pressures and reimbursement challenges.
• Patients: Benefit from innovative solutions for sleep apnea, COPD, and other chronic diseases, including expanded home-based diagnostics. Potential impacts from changes in VA disability ratings and Medicare telehealth coverage.
• Suppliers: May be affected by supply chain disruptions, trade policy changes, and increased costs for components.
• Creditors: The company's reduced long-term debt and strong cash flow improve its creditworthiness.

Next Steps

• Monitor the timing and nature of Philips' substantial return to the market and its impact on competition.
• Monitor the new CMS national coverage determination for respiratory assist devices, expected in September 2025.
• Assess the impact of potential changes to VA disability ratings for sleep apnea, which could occur in calendar year 2025.
• Evaluate the effects of the expiration of Medicare telehealth flexibilities at the end of 2025 on OSA diagnosis rates.
• Continue to evaluate the future impact of the 'One Big Beautiful Bill Act' on Medicaid funding and broader healthcare reform measures.
• Transition operations from the Chatsworth, California location to the Calabasas, California location during fiscal year 2026.
• Await the PTAB's final written decisions in the Inter Partes Review proceedings against Cleveland Medical Devices Inc. patents, expected by July 2026.
• Continue to evaluate the potential impacts of the OECD Pillar Two global minimum tax for future periods, particularly on the effective tax rate in fiscal year 2026.
• Monitor developments regarding the use of AI and ensure compliance with new AI laws and regulations, such as the Colorado AI Act taking effect in February 2026 and the EU AI Act effective August 2024.
• Close out the Corporate Integrity Agreement shortly after the end of fiscal year 2025, assuming no further inquiries from the OIG.

Key Dates

Recommendation

ResMed's fiscal year 2025 results demonstrate exceptional financial health and strategic execution, with double-digit growth in revenue, gross profit, net income, and EPS. The significant increase in cash and reduction in debt underscore robust financial management. Strategic acquisitions like VirtuOx and continuous innovation in digital health and core product lines position the company for sustained leadership in underpenetrated markets. While regulatory and competitive headwinds are acknowledged, the company's strong fundamentals, proactive R&D, and efficient operations suggest a compelling investment opportunity for long-term growth.

Keywords

Sleep Apnea, COPD, Digital Health, Medical Devices, Residential Care Software, CPAP, Ventilation, Healthcare Technology, SEC Filing, 10-K, Financial Results, Corporate Governance, Risk Management, Acquisitions, Regulatory Compliance